Melphalan Zentiva (Melphalan Hydrochloride)

Melphalan hydrochloride is an alkylating agent that forms covalent bonds with DNA, creating cross‑links that prevent DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells, leading to tumour cell death.

The dose of Melphalan Zentiva is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function, and treatment protocol. Only a qualified healthcare professional should determine the appropriate dosing schedule.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended during breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception throughout treatment and for a period afterward.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents but differs in its pharmacokinetic profile and spectrum of activity. Compared with agents like cyclophosphamide, melphalan is often preferred for certain solid tumours and haematologic cancers due to its higher potency, though it may also present a distinct toxicity profile requiring careful monitoring.

Melphalan Zentiva should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods.

Melphalan Zentiva is supplied as an intravenous solution and is administered by a qualified healthcare professional through a controlled IV infusion. The infusion rate and duration are determined by the treating physician according to the prescribed regimen and patient tolerance.

The most serious risks include severe myelosuppression leading to infections or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be closely monitored for signs of infection, bleeding, respiratory symptoms, and changes in kidney function throughout therapy.

Melphalan Zentiva is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in those with severe bone‑marrow failure, and in pregnant or nursing women. Caution is also advised for patients with significant renal or hepatic impairment.